BTB-101 (ENDOPIN)

About BTB Therapeutics

BTB Therapeutics is a private, pre-clinical stage biotech leveraging a novel transcriptomics platform to discover small molecule drugs. Its lead program, BTB-101, is a non-opioid analgesic aimed at addressing the opioid crisis, while secondary programs target rare genetic diseases like Cardiac Fabry disease and Long QT syndrome via RNA splicing modulation. The company, founded on academic research from Kyoto University, recently re-domiciled to the US, positioning itself to access larger capital and pharmaceutical markets.

Therapeutic Areas